Cargando…
Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the American Academy of Dermatology, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385551/ https://www.ncbi.nlm.nih.gov/pubmed/32735966 http://dx.doi.org/10.1016/j.jaad.2020.07.086 |
_version_ | 1783563808418037760 |
---|---|
author | Kearns, Donovan G. Chat, Vipawee S. Uppal, Shelley Wu, Jashin J. |
author_facet | Kearns, Donovan G. Chat, Vipawee S. Uppal, Shelley Wu, Jashin J. |
author_sort | Kearns, Donovan G. |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7385551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | by the American Academy of Dermatology, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73855512020-07-28 Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic Kearns, Donovan G. Chat, Vipawee S. Uppal, Shelley Wu, Jashin J. J Am Acad Dermatol JAAD Online by the American Academy of Dermatology, Inc. 2020-12 2020-07-28 /pmc/articles/PMC7385551/ /pubmed/32735966 http://dx.doi.org/10.1016/j.jaad.2020.07.086 Text en © 2020 by the American Academy of Dermatology, Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | JAAD Online Kearns, Donovan G. Chat, Vipawee S. Uppal, Shelley Wu, Jashin J. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic |
title | Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic |
title_full | Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic |
title_fullStr | Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic |
title_full_unstemmed | Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic |
title_short | Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic |
title_sort | assessing the risk of adalimumab use for hidradenitis suppurativa during the covid-19 pandemic |
topic | JAAD Online |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385551/ https://www.ncbi.nlm.nih.gov/pubmed/32735966 http://dx.doi.org/10.1016/j.jaad.2020.07.086 |
work_keys_str_mv | AT kearnsdonovang assessingtheriskofadalimumabuseforhidradenitissuppurativaduringthecovid19pandemic AT chatvipawees assessingtheriskofadalimumabuseforhidradenitissuppurativaduringthecovid19pandemic AT uppalshelley assessingtheriskofadalimumabuseforhidradenitissuppurativaduringthecovid19pandemic AT wujashinj assessingtheriskofadalimumabuseforhidradenitissuppurativaduringthecovid19pandemic |